Genetic Clues for Skin Cancer Therapies Annapolis MD

Scientists have isolated a group of genetic mutations involved in the growth of melanoma, the deadliest form of skin cancer. Their work may lead to therapies with existing drugs that target the same mutations. Led by Yardena Samuels of the National Human Genome Research Institute, the research team from the U.S. National Institutes of Health (NIH) sequenced the protein tyrosine kinase (PTK) gene family in tumor and blood samples from people with metastatic melanoma.

Lisa Joy Renfro, MD
(410) 224-2260
2002 Medical Pkwy Ste 630
Annapolis, MD
Specialties
Dermatology
Gender
Female
Education
Medical School: Univ Of Ct Sch Of Med, Farmington Ct 06032
Graduation Year: 1988

Data Provided by:
Dr.HEATHER PACHECO
# 270, 200 Harry S Truman Pkwy
Annapolis, MD
Gender
F
Speciality
Dermatologist
General Information
Accepting New Patients: Yes
RateMD Rating
5.0, out of 5 based on 1, reviews.

Data Provided by:
Jennifer Lynn Gamber, MD
600 Ridgely Ave
Annapolis, MD
Specialties
Dermatology
Gender
Female
Education
Medical School: Temple Univ Sch Of Med, Philadelphia Pa 19140
Graduation Year: 1997

Data Provided by:
Heather Andrus Pacheco
(410) 897-0272
49 Old Solomons Island Rd
Annapolis, MD
Specialty
Dermatology

Data Provided by:
David Allen Shachat, MD
(301) 262-7550
Annapolis, MD
Specialties
Dermatology
Gender
Male
Education
Medical School: Univ Of Al Sch Of Med, Birmingham Al 35294
Graduation Year: 1963

Data Provided by:
Dr.Jennifer Gamber
600 Ridgely Avenue
Annapolis, MD
Gender
F
Education
Medical School: Temple Univ Sch Of Med
Year of Graduation: 1997
Speciality
Dermatologist
General Information
Accepting New Patients: Yes
RateMD Rating
4.8, out of 5 based on 3, reviews.

Data Provided by:
Justin Theodore Roscoe, MD
(410) 224-7795
600 Ridgely Ave Ste 120
Annapolis, MD
Specialties
Dermatology
Gender
Male
Education
Medical School: Univ De Sao Paulo, Fac De Med, Sao Paulo, Sp, Brazil
Graduation Year: 1980

Data Provided by:
Gerald W Newman
(410) 224-8001
2002 Medical Pkwy
Annapolis, MD
Specialty
Dermatology

Data Provided by:
Allan Crane Harrington, MD
(410) 666-3960
101 Ridgely Ave
Annapolis, MD
Specialties
Dermatology
Gender
Male
Education
Medical School: Dartmouth Med, Hanover Nh 03755
Graduation Year: 1985

Data Provided by:
Dr.Allan Harrington
(410) 224-3614
703 Giddings Ave # M
Annapolis, MD
Gender
M
Education
Medical School: Dartmouth Med
Year of Graduation: 1985
Speciality
Dermatologist
General Information
Accepting New Patients: Yes
RateMD Rating
5.0, out of 5 based on 3, reviews.

Data Provided by:
Data Provided by:

Genetic Clues for Skin Cancer Therapies

Provided By:

MONDAY, Aug. 31 (HealthDay News) -- Scientists have isolated a group of genetic mutations involved in the growth of melanoma, the deadliest form of skin cancer. Their work may lead to therapies with existing drugs that target the same mutations.

Led by Yardena Samuels of the National Human Genome Research Institute, the research team from the U.S. National Institutes of Health (NIH) sequenced the protein tyrosine kinase (PTK) gene family in tumor and blood samples from people with metastatic melanoma. Their study is published in the September issue of the journal Nature Genetics.

"We have found what appears to be an Achilles' heel of a sizable share of melanomas," Samuels, an investigator in the cancer genetics branch of the institute's Division of Intramural Research, said in a NIH news release.

The PTK family includes many genes that, when mutated, promote many types of cancer, including brain, gastric and lung malignancies, according to background information provided in the news release. In the new NIH study, one PTK gene that appeared particularly suspicious was the ERBB4 gene. Scientists found ERBB4 mutations in 19 percent of patients' tumors, making it the most frequently mutated PTK gene in melanoma. Additional lab studies found that melanoma cells with the ERBB4 defect were dependent on the mutant gene for their growth.

The researchers also found that two additional PTK genes -- FLT1 and PTK2B -- were mutated in about 10 percent of the tumor samples.

The discoveries could open up new avenues for therapies. For example, the researchers discovered that melanoma cells grew much more slowly when exposed to lapatinib (Tykerb), a chemotherapy drug that inhibits ERBB4. Lapatinib is already in use by some breast cancer patients. The NIH team is planning a clinical trial using lapatinib in patients with metastatic melanoma harboring ERBB4 mutations.

"Though additional work is needed to gain a more complete understanding of these genetic mutations and their roles in cancer biology, our findings open the door to pursuing specific therapies that may prove useful for the treatment of melanoma with ERBB4 mutations," Samuels stated.

More information

The American Cancer Society has more on melanoma.

SOURCE: U.S. National Institutes of Health, news release, Aug. 30, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com